keyword
MENU ▼
Read by QxMD icon Read
search

Rtog

keyword
https://www.readbyqxmd.com/read/28545934/cure-modeling-in-real-time-prediction-how-much-does-it-help
#1
Gui-Shuang Ying, Qiang Zhang, Yu Lan, Yimei Li, Daniel F Heitjan
Various parametric and nonparametric modeling approaches exist for real-time prediction in time-to-event clinical trials. Recently, Chen (2016 BMC Biomedical Research Methodology 16) proposed a prediction method based on parametric cure-mixture modeling, intending to cover those situations where it appears that a non-negligible fraction of subjects is cured. In this article we apply a Weibull cure-mixture model to create predictions, demonstrating the approach in RTOG 0129, a randomized trial in head-and-neck cancer...
May 22, 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/28545199/cyberknife-radioablation-of-prostate-cancer-%C3%A2-preliminary-results-for-400-patients
#2
Leszek Miszczyk, Agnieszka Namysł Kaletka, Aleksandra Napieralska, Grzegorz Woźniak, Małgorzata Stąpór Fudzińska, Grzegorz Głowacki, Andrzej Tukiendorf
Objectives: To evaluate the tolerance and effectiveness of stereotactic ablative radiotherapy (SABR) applied in the treatment of low and intermediate risk (LR & IR) prostate cancer patients (PCP) and provide an evaluation of the level of risk group impact on treatment results. In addition, androgen deprivation therapy (ADT) usage and prostatic specific antigen (PSA) decline after SABR were assessed. Material and Methods: A total of 400 PCP (213 LR and 187 IR, including T2c) were irradiated with a CyberKnife using fd 7...
April 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28533151/low-rates-of-androgen-deprivation-therapy-use-with-salvage-radiation-therapy-in-patients-with-prostate-cancer-after-radical-prostatectomy
#3
David D Yang, Vinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, Shelby A Labe, Marie E Vastola, Ninjin Boldbaatar, Martin T King, Neil E Martin, Peter F Orio, Tni K Choueiri, Quoc-Dien Trinh, Robert B Den, Daniel E Spratt, Karen E Hoffman, Felix Y Feng, Paul L Nguyen
OBJECTIVE: The RTOG 9601 and GETUG-AFU 16 randomized controlled trials demonstrated that the addition of androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) improves progression-free and, for RTOG 9601, overall survival. We examined national trends in the use of ADT with SRT. MATERIALS AND METHODS: Of the 484,009 patients in the National Cancer Database from 2004 to 2012 with localized or locally advanced prostate cancer treated with radical prostatectomy (RP), 4,200 men received SRT (≥6mo after surgery)...
May 19, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28510808/development-of-a-contouring-guide-in-three-different-head-set-ups-for-hippocampal-sparing-radiotherapy-a-practical-approach
#4
Saide Di Biase, Marianna Trignani, Luciana Caravatta, Paul Ioan Voicu, Clelia Di Carlo, Annamaria Vinciguerra, Antonietta Augurio, Francesca Perrotti, Valentina Panara, Domenico Genovesi
BACKGROUNDS: Irradiation of the hippocampus plays a role in neurocognitive toxicity. Its delineation is complex and in practice different head position can vary hippocampus morphology on axial images; so atlas in a single standard position can result ineffective to describe different hippocampal morphologies in different head set-up. The purpose of our study was to develop a guide based on magnetic resonance imaging for hippocampus delineation in three different head set-ups. MATERIALS AND METHODS: Three patients were selected to elaborate our guide...
May 16, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28500491/hyperfractionated-accelerated-radiation-therapy-plus-cetuximab-plus-cisplatin-chemotherapy-in-locally-advanced-inoperable-squamous-cell-carcinoma-of-the-head-and-neck-final-5%C3%A2-year-results-of-a-phase%C3%A2-ii-study
#5
Thomas Kuhnt, Andreas Schreiber, Anett Pirnasch, Matthias G Hautmann, Peter Hass, Frank P Sieker, Rita Engenhart-Cabillic, Michael Richter, Kathrin Dellas, Jürgen Dunst
BACKGROUND: Cetuximab (CET) is a potent inhibitor of the epidermal growth factor receptor and has been shown to have activity in squamous cell carcinoma of the head and neck (SCCHN). We conducted a single-arm phase II trial of a combination therapy comprising cisplatin (CIS), CET and hyperfractionated accelerated radiotherapy (HART). PATIENTS AND METHODS: Patients with UICC stage III or IVA/B, M0 SCCHN were enrolled and treated with an initial dose of CET (400 mg/m(2)) and then with a weekly dosage of 250 mg/m(2) during HART...
May 12, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28495444/comparing-the-rtog-eortc-and-lent-soma-scoring-systems-for-the-evaluation-of-late-skin-toxicity-after-125-i-seed-brachytherapy-for-parotid-gland-cancer
#6
Ming-Hui Mao, Zhien Feng, Hua Li, Li-Zheng Qin, Jian-Hua Li, Xin Huang, Ru-Dong Xing, Jie Zhang, Jian-Guo Zhang, Zheng-Xue Han
PURPOSE: The Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force-Subjective, Objective, Management and Analytic (LENT-SOMA) scoring systems were compared for grading late skin effects after iodine-125 seed brachytherapy in parotid gland cancer patients. METHODS AND MATERIALS: A total of 109 patients diagnosed with parotid gland carcinoma were treated postoperatively with iodine-125 seed brachytherapy at a dose of 100-120 Gy. After 6-24 months of followup, telangiectasia, skin pigmentation, atrophy, fibrosis, and ulceration were scored according to both RTOG and LENT-SOMA scale criteria...
May 8, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28485342/preoperative-long-course-chemoradiation-for-localized-rectal-cancer-a-retrospective-comparison-of-response-and-outcome-between-5-fluorouracil-leucovorin-versus-capecitabine
#7
B Kunheri, B Gurram, R Madhavan, D Makuny
BACKGROUND: Preoperative concurrent chemoradiation therapy (CRT) with either capecitabine or 5-florouracil/leucovorin (5 FU/LV) is the standard of care in locally advanced rectal cancer (LARC). Literature comparing the toxicity and response of these two regimens in Indian patients is sparse. Our objective was to compare the pathological response (PR) and clinical outcome of capecitabine versus 5 FU/LV in CRT for LARC. MATERIALS AND METHODS: Sixty patients with LARC treated with preoperative CRT with capecitabine or 5FU/LV from January 2009 to May 2014 were analyzed...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28479012/whole-brain-irradiation-field-design-a-comparison-of-parotid-dose
#8
Cheng-Chia Wu, Yen-Ruh Wuu, Ashish Jani, Anurag Saraf, Cheng-Hung Tai, Matthew E Lapa, Jacquelyn I S Andrew, Akhil Tiwari, Heva J Saadatmand, Steven R Isaacson, Simon K Cheng, Tony J C Wang
Whole-brain radiation therapy (WBRT) plays an important role in patients with diffusely metastatic intracranial disease. Whether the extent of the radiation field design to C1 or C2 affects parotid dose and risk for developing xerostomia is unknown. The goal of this study is to examine the parotid dose based off of the inferior extent of WBRT field to either C1 or C2. Patients treated with WBRT with either 30 Gy or 37.5 Gy from 2011 to 2014 at a single institution were examined. Parotid dose constraints were compared with Radiation Therapy Oncology Group (RTOG) 0615 nasopharyngeal carcinoma for a 33-fraction treatment: mean <26 Gy, volume constraint at 20 Gy (V20) < 20 cc, and dose at 50% of the parotid volume (D50) < 30 Gy...
May 4, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28476138/a-comprehensive-dosimetric-study-on-switching-from-a-type-b-to-a-type-c-dose-algorithm-for-modern-lung-sbrt
#9
Christina Zhou, Nathan Bennion, Rongtao Ma, Xiaoying Liang, Shuo Wang, Kristina Zvolanek, Megan Hyun, Xiaobo Li, Sumin Zhou, Weining Zhen, Chi Lin, Andrew Wahl, Dandan Zheng
BACKGROUND: Type-C dose algorithms provide more accurate dosimetry for lung SBRT treatment planning. However, because current dosimetric protocols were developed based on conventional algorithms, its applicability for the new generation algorithms needs to be determined. Previous studies on this issue used small sample sizes and reached discordant conclusions. Our study assessed dose calculation of a Type-C algorithm with current dosimetric protocols in a large patient cohort, in order to demonstrate the dosimetric impacts and necessary treatment planning steps of switching from a Type-B to a Type-C dose algorithm for lung SBRT planning...
May 5, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28464906/adjuvant-radiotherapy-after-radical-cystectomy-for-patients-with-muscle-invasive-bladder-cancer-a-phase-ii-trial
#10
Valérie Fonteyne, Piet Dirix, Sara Junius, Elke Rammant, Piet Ost, Gert De Meerleer, Martijn Swimberghe, Karel Decaestecker
BACKGROUND: Neo-adjuvant chemotherapy followed by radical cystectomy with extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC). Despite this aggressive treatment the outcome is poor and ultimately, 30% of the patients with ≥pT3 tumors develop a pelvic recurrence. We hypothesize that postoperative adjuvant external beam radiotherapy (EBRT) might prevent local and lymph node recurrence and improve disease free- and overall survival as loco-regional recurrence is linked to the development of distant metastasis...
May 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28463161/feasibility-of-patient-reporting-of-symptomatic-adverse-events-via-the-patient-reported-outcomes-version-of-the-common-terminology-criteria-for-adverse-events-pro-ctcae-in-a-chemoradiotherapy-cooperative-group-multicenter-clinical-trial
#11
Ethan Basch, Stephanie L Pugh, Amylou C Dueck, Sandra A Mitchell, Lawrence Berk, Shannon Fogh, Lauren J Rogak, Marcha Gatewood, Bryce B Reeve, Tito R Mendoza, Ann M O'Mara, Andrea M Denicoff, Lori M Minasian, Antonia V Bennett, Ann Setser, Deborah Schrag, Kevin Roof, Joan K Moore, Thomas Gergel, Kevin Stephans, Andreas Rimner, Albert DeNittis, Deborah Watkins Bruner
PURPOSE: To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter clinical trial using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). METHODS AND MATERIALS: Patients enrolled in NRG Oncology's RTOG 1012 (Prophylactic Manuka Honey for Reduction of Chemoradiation Induced Esophagitis-Related Pain during Treatment of Lung Cancer) were asked to self-report 53 PRO-CTCAE items representing 30 symptomatic AEs at 6 time points (baseline; weekly ×4 during treatment; 12 weeks after treatment)...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28463160/predictors-of-radiation-therapy-related-gastrointestinal-toxicity-from-anal-cancer-dose-painted-intensity-modulated-radiation-therapy-secondary-analysis-of-nrg-oncology-rtog-0529
#12
Jeffrey R Olsen, Jennifer Moughan, Robert Myerson, Andre Abitbol, Desiree E Doncals, Douglas Johnson, Tracey E Schefter, Yuhchyau Chen, Barbara Fisher, Jeff Michalski, Samir Narayan, Albert Chang, Christopher H Crane, Lisa Kachnic
PURPOSE: NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer. This secondary analysis was performed to identify patient and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs). METHODS AND MATERIALS: NRG Oncology RTOG 0529 treatment plans were reviewed to extract dose-volume data for tightly contoured small bowel, loosely contoured anterior pelvic contents (APC), and uninvolved colon outside the target volume (UC)...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28463149/duration-of-androgen-deprivation-in-locally-advanced-prostate-cancer-long-term-update-of-nrg-oncology-rtog-9202
#13
Colleen A F Lawton, Xiaolei Lin, Gerald E Hanks, Herbert Lepor, David J Grignon, Harmar D Brereton, Meena Bedi, Seth A Rosenthal, Kenneth L Zeitzer, Varagur M Venkatesan, Eric M Horwitz, Thomas M Pisansky, Harold Kim, Matthew B Parliament, Rachel Rabinovitch, Mack Roach, Young Kwok, James J Dignam, Howard M Sandler
PURPOSE: Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. METHODS AND MATERIALS: Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28457817/-comparison-of-survival-and-chronic-gastrointestinal-toxicities-in-patients-with-locally-advanced-cervical-cancer-treated-by-conventional-or-intensity-modulated-radiation-technique
#14
C Gamelon-Bénichou, S Oldrini, C Charra-Brunaud, G Vogin, J Salleron, D Peiffert
PURPOSE: To evaluate prospectively chronic gastrointestinal toxicity in patients with cervical cancer treated with conventional irradiation or with intensity-modulated irradiation (IMRT). PATIENTS AND METHODS: Between June 2005 and September 2013, 109 patients underwent external radiotherapy followed by brachytherapy for cervical cancer at the "Institut de Cancérologie de Lorraine". Each patient receiving IMRT was paired with a patient receiving conventional radiotherapy on the following criteria: concomitant chemotherapy, additional nodal dose, treatment of para-aortic lymph node area, age...
April 27, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28457723/dosimetric-effect-of-multileaf-collimator-leaf-width-on-volumetric-modulated-arc-stereotactic-radiotherapy-for-spine-tumors
#15
Ahmad Amoush, Huang Long, Laxmi Subedi, Peng Qi, Toufik Djemil, Ping Xia
This work aimed to study the dosimetric effect of multileaf collimator (MLC) leaf widths in treatment plans for patients receiving volumetric modulated arc therapy (VMAT) for spine stereotactic body radiation therapy (SBRT). Thirteen patients treated with spine SBRT were retrospectively selected for this study. The patients were treated following the protocol of the Radiation Therapy Oncology Group 0631 (RTOG 0631) for spine metastasis. The prescription dose was 16 Gy in 1 fraction to 90% of the target volume (V16 > 90%)...
April 28, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28453749/an-independently-validated-nomogram-for-individualized-estimation-of-survival-among-patients-with-newly-diagnosed-glioblastoma-nrg-oncology-rtog-0525-and-0825
#16
Haley Gittleman, Daniel Lim, Michael W Kattan, Arnab Chakravarti, Mark R Gilbert, Andrew B Lassman, Simon S Lo, Mitchell Machtay, Andrew E Sloan, Erik P Sulman, Devin Tian, Michael A Vogelbaum, Tony J C Wang, Marta Penas-Prado, Emad Youssef, Deborah T Blumenthal, Peixin Zhang, Minesh P Mehta, Jill S Barnholtz-Sloan
Background.: Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram to estimate individualized survival probabilities for patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Oncology Group (RTOG) clinical trials. Methods.: This analysis included information on 799 (RTOG 0525) and 555 (RTOG 0825) eligible and randomized patients with newly diagnosed GBM and contained the following variables: age at diagnosis, race, gender, Karnofsky performance status (KPS), extent of resection, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and survival (in months)...
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28453703/heart-dose-exposure-as-prognostic-marker-after-radiotherapy-for-resectable-stage-iiia-b-non-small-cell-lung-cancer-secondary-analysis-of-a-randomized-trial
#17
M Guberina, W Eberhardt, M Stuschke, T Gauler, F Heinzelmann, D Cheufou, M Kimmich, G Friedel, H Schmidberger, K Darwiche, V Jendrossek, M Schuler, G Stamatis, C Pöttgen
Background: Heart exposure to ionizing irradiation can cause ischaemic heart disease. The partial heart volume receiving ≥5 Gy (heartV5) was supposed to be an independent prognostic factor for survival after radiochemotherapy for locally advanced non-small-cell lung cancer (NSCLC). But validation of the latter hypothesis is needed under the concurrent risks of lung cancer patients. Patients and methods: The ESPATUE phase III trial recruited patients with potentially operable IIIA(N2)/selected IIIB NSCLC between 01/2004 and 01/2013...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28433413/stereotactic-ablative-radiotherapy-in-the-treatment-of-low-and-intermediate-risk-prostate-cancer-is-there-an-optimal-dose
#18
Joelle Helou, Laura D'Alimonte, Harvey Quon, Andrea Deabreu, Kristina Commisso, Patrick Cheung, William Chu, Alexandre Mamedov, Melanie Davidson, Ananth Ravi, Andrew Loblaw
PURPOSE: To investigate if stereotactic ablative radiotherapy (SABR) dose is associated with PSA at 3years (PSA3y) in the treatment of localized prostate cancer and to explore predictors of late genitourinary (GU) toxicity. MATERIALS AND METHODS: Three prospective trials of SABR were undertaken at our institution: 1) 35Gy/5 fractions/29days; 2) 40Gy/5 fractions/29days; 3) 40Gy/5 fractions/11 or 29days. PSA3y was analyzed as a continuous variable. Toxicity was defined as the worst new toxicity and assessed using the radiation therapy oncology group (RTOG) late morbidity scheme...
April 19, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28428149/local-control-and-toxicity-of-adaptive-radiotherapy-using-weekly-ct-imaging-results-from-the-lartia-trial-in-stage-iii-nsclc
#19
Sara Ramella, Michele Fiore, Sonia Silipigni, Maria Cristina Zappa, Massimo Jaus, Antonio Maria Alberti, Paolo Matteucci, Elisabetta Molfese, Patrizia Cornacchione, Carlo Greco, Lucio Trodella, Edy Ippolito, Rolando Maria D'Angelillo
INTRODUCTION: Anatomical change of tumor during radiotherapy contributes to target missing. However, in the case of tumor shrinkage, adaptation of volume could result in an increased incidence of recurrence in the area of target reduction. This study aims to investigate the incidence of failure of the adaptive approach and, in particular, the risk for local recurrence in the area excluded after replanning. METHODS: In this prospective study, patients with locally advanced NSCLC treated with concomitant chemoradiation underwent weekly chest computed tomography simulation during treatment...
April 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28407345/dosimetric-impacts-of-endorectal-balloon-in-cyberknife-stereotactic-body-radiation-therapy-sbrt-for-early-stage-prostate-cancer
#20
Hong F Xiang, Hsiao-Ming Lu, Jason A Efstathiou, Anthony L Zietman, Ricardo De Armas, Kathryn Harris, B Nicolas Bloch, Muhammad Mustafa Qureshi, Sean Keohan, Ariel E Hirsch
PURPOSE: In SBRT for prostate cancer, higher fractional dose to the rectum is a major toxicity concern due to using smaller PTV margin and hypofractionation. We investigate the dosimetric impact on rectum using endorectal balloon (ERB) in prostate SBRT. MATERIALS AND METHODS: Twenty prostate cancer patients were included in a retrospective study, ten with ERB and 10 without ERB. Optimized SBRT plans were generated on CyberKnife MultiPlan for 5 × 7.25 Gy to PTV under RTOG-0938 protocol for early-stage prostate cancer...
April 13, 2017: Journal of Applied Clinical Medical Physics
keyword
keyword
43154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"